" Abzena, a leading CDMO/CRO, now offers GMP cell-based potency assays at its UK and US sites, enhancing its support for complex biologics and ADC programs...
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced the presentation of new results from its Phase 1 study ...
Bristol Myers Squibb (NYSE: BMY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Amgen (NASDAQ:AMGN) announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheum...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology ...
BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) announced the signing of a definitive agreement for...
Gilead Sciences, Inc. (Nasdaq: GILD) presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is stu...
NurExone Biologic Inc. a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that the European Medici...
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant adv...
GSK plc (LSE/NYSE: GSK) announced the results of a GSK-sponsored multinational survey designed to raise awareness of challenges that people with gynaecolog...
Alexion, AstraZeneca Rare Disease and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced positive topline results from the ...
IDEAYA Secures Exclusive Global License for Biocytogen’s First-In-Class BsADC, B7H3/PTK7 Topo-I Payload (IDE034), Validating Biocytogen’s Ren...
First and only NMPA-approved treatment for patients with CIDP in China Third approval for efgartigimod franchise in China demonstrating Zai Lab&rs...
© 2024 Biopharma Boardroom. All Rights Reserved.
